

# UCSF

## UC San Francisco Previously Published Works

### Title

Ethnic Differences in Atrial Fibrillation in the United Kingdom.

### Permalink

<https://escholarship.org/uc/item/7882d7sg>

### Journal

JACC: Advances, 3(12)

### Authors

Frimodt-Møller, Emilie

Tang, Janet

Biering-Sørensen, Tor

et al.

### Publication Date

2024-12-01

### DOI

10.1016/j.jacadv.2024.101043

Peer reviewed

## ORIGINAL RESEARCH

## RHYTHM DISORDERS AND ELECTROPHYSIOLOGY

# Ethnic Differences in Atrial Fibrillation in the United Kingdom



Emilie K. Fridodt-Møller, MD,<sup>a,b</sup> Janet J. Tang, PhD, MPH,<sup>a</sup> Tor Biering-Sørensen, MD, MSc, MPH, PhD,<sup>b,c</sup> Francesca N. Delling, MD, MPH,<sup>a</sup> Larry R. Jackson II, MD, MHSc,<sup>d</sup> Gregory M. Marcus, MD, MAS<sup>a</sup>

## ABSTRACT

**BACKGROUND** Within the United States, White individuals experience a higher risk of atrial fibrillation (AF) while exhibiting a lower AF-related stroke risk compared to other ethnic groups. It is possible that these observations stem from phenomena unique to the United States, such as differential health care access. The United Kingdom provides socialized medicine, which ostensibly promotes equitable health care access.

**OBJECTIVES** The purpose of the study was to examine whether ethnic differences in the risks of AF and AF-related stroke and systemic infarcts exist in the United Kingdom.

**METHODS** We leveraged longitudinal data from the UK Biobank between January 1, 2006, and June 30, 2020. Ethnicity was categorized as White, Black, South Asian, Chinese, or multiracial. Incident AF, stroke, and systemic infarct were ascertained from in- and out-patient records.

**RESULTS** A total of 458,785 participants (438,333 White, 7,244 Black, 9,143 South Asian, 1,376 Chinese, and 2,689 multiracial) were included. After excluding those with prevalent AF, 8,706 developed incident AF. Black individuals (HR: 0.60; 95% CI: 0.49-0.74;  $P < 0.001$ ), South Asians (HR: 0.59; 95% CI: 0.49-0.72;  $P < 0.001$ ), and Chinese (HR: 0.31; 95% CI: 0.12-0.83;  $P = 0.002$ ) each exhibited substantially lower risks of AF compared to White individuals after multivariable adjustment. In AF participants, incident stroke and systemic infarct occurred in 1,550. No significant differences in the risk of AF-related stroke and systemic infarcts by ethnicity were detected, but small numbers of these events were present.

**CONCLUSIONS** In a European population with universal access to health care, White individuals consistently experienced the highest risk of AF, but there were no detectable differences in AF-related stroke or systemic infarcts. (JACC Adv. 2024;3:101043) © 2024 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

**A**trial fibrillation (AF) is the most common sustained arrhythmia worldwide and is associated with increased morbidity, including stroke, heart failure, and overall mortality.<sup>1-3</sup> Within the

United States, White individuals experience a higher risk of AF compared to other racial and ethnic populations.<sup>4-9</sup> The mechanisms underlying these phenomena are largely unknown, but several theories have

From the <sup>a</sup>Division of Cardiology, University of California-San Francisco, San Francisco, California, USA; <sup>b</sup>Department of Cardiology, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark; <sup>c</sup>Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; and the <sup>d</sup>Division of Cardiology, Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA.

The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors' institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the [Author Center](#).

Manuscript received January 9, 2024; revised manuscript received March 6, 2024, accepted April 16, 2024.

**ABBREVIATIONS  
AND ACRONYMS****AF** = atrial fibrillation**ICD** = International  
Classification of Diseases

been proposed, including the influence of inherited genetic variants more common with European ancestry<sup>10,11</sup> or disparities in health care access leading to enhanced AF detection in white individuals.<sup>9</sup>

AF is the most common cause of ischemic stroke, increasing the risk by 4- to 5-fold.<sup>12</sup> Racial and ethnic differences in AF-related ischemic stroke have also been reported in the U.S. population, with evidence that American Indian and Alaska Native populations, Hispanics, and non-Hispanic black individuals each experienced a higher risk of AF-related stroke compared to white individuals.<sup>13,14</sup>

The observations of racial and ethnic differences in AF and AF-related stroke might stem from phenomena unique to the United States, such as differential access to health care, social determinants of health, suboptimal clinician-patient communication, a lack of trust among some groups related to U.S.-specific research history,<sup>15</sup> or issues pertinent to unique environments. The observed differences may represent something more universal to different racial and ethnic groups that may prove informative and useful to all AF patients, regardless of race or ethnicity. The United Kingdom provides socialized medicine, which at least affords the opportunity for equal access to health care regardless of race or ethnicity. To our knowledge, this is the first study using longitudinal data from the UK Biobank to examine whether ethnic differences in AF and AF-related stroke and systemic embolism risk persist in a country outside the United States.

**METHODS**

The UK Biobank is a publicly available population-based prospective cohort study, approved by the National Information Governance Board for Health and Social Care and the National Health Service (NHS) North West Multicenter Research Ethics Committee. Details about the UK Biobank have been described elsewhere.<sup>16</sup> Recruitment was conducted between 2006 and 2010 through postal invites of individuals aged between 40 and 69 years identified through NHS registers. All individuals living within 10 miles of one of the 22 UK Biobank assessment centers were invited to participate. Around 500,000 participants were included in the study cohort, of which 94.5% were of White ethnicity. This distribution exhibited a slightly higher proportion of White individuals compared to the national population of the same age range in the

2011 UK Census for England, Wales, and Scotland (91.3%).<sup>17</sup>

Extensive questionnaire data (completed as self-administered touchscreen and nurse-led questionnaire), physical measures, and biological samples were collected at recruitment, with ongoing enhanced data collection in large subsets of the cohort. The participants also provided consent for prospective data linkage to national electronic health-related data sets. All participants provided informed consent.<sup>16</sup>

**STUDY POPULATION.** Participants with ethnicity defined as missing, “do not know” or “prefer not to answer” (n = 2,777), or “other ethnic group” (n = 4,558) were excluded.

**ETHNICITY.** Ethnicity was self-identified and categorized as White (including British, Irish, or “any other White background”), Black (including Caribbean, African, or “any other Black background”), South Asian (including Indian, Pakistani, Bangladeshi, or “any other Asian background”), Chinese, or multiracial (including White and Black Caribbean, White and Black African, White and Asian, or “any other mixed background”). Based on the geographic differentiation of South Asian and Chinese and collapsing of categories as described above, and in accordance with the UK NHS’s ethnicity categories,<sup>18</sup> the groups were categorized as ethnicities rather than races.

**COVARIATE ASSESSMENT.** Baseline age and sex were obtained from the initial assessment visit. Educational level was self-reported. Body mass index was derived from height and weight measurements at the initial assessment and calculated as weight in kilograms divided by height in meters squared (kg/m<sup>2</sup>). Information on baseline comorbidities including diabetes, hypertension, coronary disease, valvular disease, congestive heart failure, chronic kidney disease, and obstructive sleep apnea were considered present if self-reported or if listed as primary or secondary diagnosis in in- and out-patient reports with International Classification of Diseases-9th Revision (ICD-9) and International Statistical Classification of Diseases and Related Health Problems-10th Revision (ICD-10) codes by the time of the first study visit (Supplemental Table 1). Smoking and alcohol use were self-reported at recruitment.

**OUTCOME ASCERTAINMENT.** Incident outcomes, including AF, ischemic stroke, and systemic infarcts

were ascertained from January 1, 2006, through June 30, 2020, and defined as not having the condition prior to (and including) recruitment but subsequently developing the diagnosis during the study period. AF (including paroxysmal, persistent, and chronic AF), ischemic stroke (including nonhemorrhagic stroke and transient ischemic attack), and systemic infarctions (including retinal infarctions, ischemic deafness, pulmonary embolisms and infarctions, aorta, mesenteric, hepatic, and renal infarctions, infarctions in the extremities, and embolism and thrombosis of other specified artery) were assessed from in- and out-patient reports determined by ICD-9 and ICD-10 codes for the diseases listed as either a primary or secondary diagnosis ([Supplemental Table 1](#)). Myocardial infarction was not included since the etiology of myocardial infarction may more likely be due to coronary atherosclerosis than embolism.

**STATISTICAL ANALYSIS.** Normally distributed continuous variables are described as mean  $\pm$  SD and tests for differences in the means are used in one-way analysis of variance and unpaired, 2-tailed *t* tests. Continuous variables without a normal distribution are presented as median (IQR) and were compared using the Wilcoxon rank-sum test. Categorical variables were compared using chi-squared tests.

Incidence rates per 100,000 person-years were calculated, and incidence rate ratios were assessed using Poisson's regression. Incidence rates and ratios were restricted to those without prevalent AF, defined as the presence of AF before or on the recruitment date ( $n = 2,226$ ).

Unadjusted and adjusted Cox proportional hazards regression models were used to assess the relationship between ethnicity and incident AF. Regression analyses were restricted to those without prevalent AF. Participants were censored at the time of their AF diagnosis, death, or the end of the study period (June 30, 2020), whichever came first.

Comparisons of a combined endpoint, including ischemic stroke and systemic infarct incidence, in those with AF according to ethnicity were made using Cox proportional hazards regression models before and after multivariable adjustment. Given a small population of Black, South Asian, Chinese, and multiracial individuals with AF and in order to obtain as full an assessment as possible regarding stroke and systemic infarcts as a complication of AF, all

participants with prevalent AF (thus, any history of AF prior to and including the recruitment date) in addition to anyone with any AF throughout follow-up were included in the stroke and systemic infarct analyses. Participants with prevalent ischemic stroke or systemic infarct were excluded from the analyses ( $n = 9,685$ ). For incident ischemic stroke and systemic infarcts, participants were censored at the time of their first ischemic stroke or systemic infarct diagnosis after the baseline visit, at death, or at the end of the study period.

A sensitivity analysis was conducted that limited the outcome to stroke alone. Participants with prevalent stroke were excluded ( $n = 5,718$ ). Interaction analyses were performed to determine whether ethnicity was an effect modifier of the AF-stroke relationship.

Potential confounders and mediators were included as covariates in multivariable models based on previous literature. This included age, sex, education, body mass index, diabetes, hypertension, coronary disease, valvular disease, congestive heart failure, chronic kidney disease, obstructive sleep apnea, smoking, and alcohol.

A 2-tailed  $P < 0.05$  was considered to be statistically significant. All statistical analyses were performed using SAS (version 9.4).

## RESULTS

**BASELINE CHARACTERISTICS.** A total of 458,785 participants (438,333 White, 7,244 Black, 9,143 South Asian, 1,376 Chinese, and 2,689 multiracial) were included. The baseline characteristics between groups were heterogeneous and exhibited statistically significant differences in every covariate assessed except for valvular disease ([Table 1](#)). White individuals were, on average, older, less educated, more often had prevalent AF, and consumed alcohol more frequently.

**ETHNICITY AND ATRIAL FIBRILLATION.** During a mean follow-up of  $11.1 \pm 1.7$  years, 8,706 participants exhibited incident AF. The type of AF first detected according to ethnicity is presented in [Supplemental Table 2](#). Incidence rates of AF were significantly lower in all underrepresented ethnic groups compared to White individuals ([Figure 1](#)).

Black, South Asian, Chinese, and multiracial individuals each exhibited substantially lower risks of incident AF compared to White individuals in

<b>TABLE 1 Baseline Characteristics</b>						
	<b>White (n = 438,333)</b>	<b>Black (n = 7,244)</b>	<b>South Asian (n = 9,143)</b>	<b>Chinese (n = 1,376)</b>	<b>Multiracial (n = 2,689)</b>	<b>P Value</b>
Age, y	57 ± 8	52.2 ± 8.2	53.6 ± 8.5	52.7 ± 7.7	52 ± 8.2	<0.001
Female	239,828 (54.7)	4,302 (59.4)	4,288 (46.9)	880 (64)	1,791 (63.3)	<0.001
Education						<0.001
O levels or equivalent	141,997 (33)	1,759 (25.2)	2,194 (25.6)	316 (24.3)	776 (29.6)	
CSEs or equivalent	52,489 (12.2)	1,335 (19.2)	949 (11)	83 (6.4)	386 (14.7)	
College or university degree	135,800 (31.5)	2,307 (33.1)	3,460 (40.3)	656 (50.4)	1,006 (38.4)	
Other professional	22,671 (5.3)	555 (8)	412 (4.8)	96 (7.4)	117 (4.5)	
None of the above	78,154 (18)	1,012 (14.5)	1,564 (18.2)	150 (11.5)	338 (12.9)	
Mean body mass index, kg/m <sup>2</sup>	27.5 ± 4.8	29.6 ± 5.5	27.2 ± 4.4	24.2 ± 3.5	27.5 ± 5.3	<0.001
Prevalent atrial fibrillation	2,183 (0.5)	9 (0.1)	28 (0.3)	1 (0.07)	5 (0.2)	<0.001
Diabetes	14,068 (3.2)	456 (6.3)	1,123 (12.3)	43 (3.1)	92 (3.4)	<0.001
Hypertension	62,259 (14.2)	1,336 (18.4)	1,811 (19.8)	125 (9.1)	301 (11.2)	<0.001
Coronary disease	15,254 (3.5)	142 (2)	620 (6.8)	22 (1.6)	55 (2)	<0.001
Valvular disease	4,734 (1.1)	74 (1)	87 (1)	11 (0.8)	18 (0.7)	0.15
Congestive heart failure	17,141 (3.9)	238 (3.3)	528 (5.8)	37 (2.7)	102 (3.8)	<0.001
Chronic kidney disease	26,901 (6.1)	513 (7.1)	932 (10.2)	41 (3)	117 (4.4)	<0.001
Obstructive sleep apnea	3,217 (0.7)	59 (0.8)	85 (0.9)	3 (0.2)	20 (0.7)	0.035
Smoking						<0.001
Prefer not to answer	1,606 (0.4)	55 (0.8)	106 (1.2)	4 (0.3)	14 (0.5)	
Never	233,150 (53.2)	5,003 (69.1)	6,992 (76.5)	1,085 (78.9)	1,273 (47.3)	
Previous	157,059 (35.8)	1,278 (17.6)	1,202 (13.1)	191 (13.9)	891 (33.1)	
Current	46,518 (10.6)	908 (12.5)	843 (9.2)	96 (7)	511 (19)	
Alcohol						<0.001
Prefer not to answer	328 (0.07)	28 (0.4)	56 (0.6)	2 (0.1)	5 (0.2)	
Never	30,425 (6.9)	1,616 (22.3)	4,175 (45.7)	385 (28)	314 (11.7)	
On special occasions	48,560 (11)	2,079 (28.7)	1,663 (18.2)	486 (35.3)	496 (18.4)	
1-3 times a month	49,230 (11.2)	942 (13)	663 (7.3)	150 (10.9)	390 (14.5)	
1-2 times a week	115,238 (26.3)	1,429 (19.7)	1,220 (13.3)	180 (13)	636 (23.7)	
3-4 times a week	103,190 (23.5)	692 (9.6)	754 (8.2)	81 (5.9)	450 (16.7)	
Daily	91,362 (21)	458 (6.3)	612 (6.7)	92 (6.7)	398 (14.8)	

Values are mean ± SD, n (%), or median (IQR). Baseline characteristics of study population according to ethnicity.  
CSE = Certificate of Secondary Education; O levels = ordinary levels.

unadjusted analyses, which remained significant for Black, South Asian, and Chinese individuals after multivariable adjustment (**Figure 2, Central Illustration**).

**ATRIAL FIBRILLATION-RELATED STROKE AND SYSTEMIC INFARCTS.** Among those without prevalent stroke or systemic infarcts, AF was detected in 10,172 (prior to recruitment or during follow-up). Incident ischemic stroke and systemic infarcts occurred in 1,550 (1,513 in White individuals vs 37 in the rest of the cohort with AF). The number of events according to each ethnic subgroup is presented in **Supplemental Table 3**. There were no differences in the risk of ischemic stroke and systemic infarcts among those of the underrepresented ethnic populations compared to White individuals nor were there any differences in risk when stratified by each ethnicity (**Table 2, Supplemental Figure 1**). In sensitivity analyses, multiracial individuals had a higher risk of ischemic stroke in both

unadjusted (HR: 2.42; 95% CI: 1.15-5.10;  $P = 0.02$ ) and adjusted analyses (HR: 2.25; 95% CI: 1.01-5.04;  $P = 0.048$ ) compared to White individuals, whereas there were no differences in the risk of stroke between the remaining ethnicities relative to White individuals (**Table 3**). However, small numbers of ischemic stroke and systemic infarct events among the underrepresented ethnic groups were present. Ethnicity did not modify the relationship between AF and ischemic stroke ( $P = 0.71$ ).


## DISCUSSION

In the United Kingdom, White individuals experienced the highest risks of developing AF, consistent with multiple studies in the United States. Contrary to prior U.S. investigations, no statistically significant differences in the risk of ischemic stroke and systemic infarcts by ethnicity were observed, although insufficient power may have explained those negative

results, and firm conclusions in relation to this should be drawn with caution.

To our knowledge, this is the first study investigating ethnic differences in AF and AF-related stroke and systemic infarct risk in a country outside the United States using longitudinal data from a large-scale population-based cohort. Previous studies outside the United States have been limited to: cross-sectional analyses,<sup>19,20</sup> assessing individuals from both Europe, Asia, and North America utilizing different study design and ascertainment that varied by country,<sup>21</sup> assessing hospitalized patients admitted with nonhemorrhagic stroke,<sup>22</sup> or only involving patients with validated heart failure across Asia.<sup>23</sup> Our study benefited from the size and quality of the UK Biobank, providing analyses from a comprehensive cohort including more than 450,000 individuals and allowing for linkage to longitudinal, national health data. While the majority of the study population consisted of White individuals, each of the underrepresented ethnic groups was still represented by thousands of individuals (each group representing larger numbers than those in many previous studies).<sup>21-23</sup> However, the ethnic distribution may not be truly representative of the current UK population, where 81.7% of the population were considered ethnic White in the 2021 Census,<sup>24</sup> limiting the generalizability of our findings. This highlights the need to improve recruitment of diverse ethnic populations in future studies to address such limitations and enhance generalizability across all ethnic groups.


**ADDRESSING POTENTIAL BIASES.** A higher prevalence and incidence of AF among non-Hispanic White populations have been consistently observed.<sup>4-6,10,25</sup> It is possible these observed differences occur as a result of racial or ethnic disparities due to differences related to symptom reporting, ascertainment of AF, or reduced health care access. Prior studies within the United States have attempted to address those potential explanations in several ways, including: performing negative control analyses (demonstrating different patterns among diagnoses other than AF),<sup>4</sup> by showing more AF on baseline ECGs dictated by study cohort participation and therefore not relying on clinical health care settings,<sup>5</sup> by assessing patients with continuous heart-rhythm monitoring via indwelling pacemakers,<sup>26</sup> and by showing an increasing risk of AF among self-identified African Americans exhibiting more genotype-determined European ancestry.<sup>10</sup> To our knowledge, only 1 study suggested that AF may be less common in non-Hispanic Whites. However, the possibility that



non-Hispanic Whites more often had diagnosed AF treated with various rhythm control strategies (such as antiarrhythmic drugs and/or ablation) could not be excluded in that study.<sup>27</sup>

**CONTRIBUTING FACTORS TO THE ETHNICITY-ATRIAL FIBRILLATION RELATIONSHIP.**

Apart from issues of misclassification or ascertainment, other factors that may contribute to the elevated AF risk in White individuals are not well understood. These may include genetic effects,<sup>10,11</sup> structural or hormonal effects such as larger left atrial diameter<sup>5</sup> or higher atrial natriuretic peptide levels in White individuals,<sup>7</sup> or differential environmental exposures related to ethnicity. In the current study population, White individuals were older and more likely to consume alcohol; both characteristics have been associated with higher risk of incident AF (both long-term alcohol consumption and as an acute trigger of a new AF episode).<sup>28-30</sup> While these factors may have contributed to the increased risk of AF within White individuals in the present study, the observed ethnic differences persisted despite



multivariable adjustment for both age and alcohol consumed.


Our findings in a country outside the United States that offers socialized medicine demonstrate that the phenomenon is not unique to the United States. As the United Kingdom is European and also predominately White, we cannot exclude the possibility that similar causal phenomena still play a role. However, as the geographic location and history of these countries are substantially different, the consistent findings now demonstrated outside the United States may provide additional evidence that AF risk is different as a function of ethnicity, regardless of the specific environment.

**STROKE AND SYSTEMIC INFARCTS RISK.** The major adverse consequence of AF is an ischemic stroke.<sup>31</sup> In contrast to the consistent observations in the United States that under-represented racial and ethnic groups experience a higher risk of AF-related stroke,<sup>13,32,33</sup> we were unable to demonstrate similarly statistically significant findings in the United Kingdom. The inclusion of systemic infarcts to increase the number of events (and therefore power) generally did not result in statistically significant results. Of note, sensitivity analyses did suggest a higher risk of ischemic stroke among multiracial individuals compared to White individuals; given the

absence of similar findings in each ethnic group alone, this unique finding may reflect a cultural or social phenomenon rather than a biological one and is worthy of future study. While insufficient power to detect significant differences may explain our negative findings, those small numbers were driven by the fact that several ethnic groups exhibited a particularly low prevalence and incidence of AF. It is therefore possible that these observations represent a real phenomenon that is different than what has been observed in the United States. It is worth highlighting that White individuals in the United Kingdom were, on average, less educated than other groups. Although we adjusted for covariates found to be significantly different, these observations may yet demonstrate the importance of socioeconomic factors pertinent to AF-related stroke and systemic embolism.

**STUDY LIMITATIONS.** Important limitations must be acknowledged. This is an observational study describing epidemiologic phenomena, and the study is not designed to elucidate causal mechanisms. For example, differences in various therapies to prevent stroke, such as more guideline-adherent anticoagulation or control of hypertension with less disparities between ethnicities in the United Kingdom, may underlie the observations made. While associations observed may be explained by residual mediation or confounding, the identification of such responsible factors would in fact be valuable in revealing factors pertinent to AF risk. Our findings are generally dependent on the accuracy of self-reported ethnicity, but even though admixed populations exist, ethnicity self-identification has been demonstrated to correlate well with genetic ancestry<sup>34</sup> and should capture social aspects of self-determined identity. As participants had to be interested and able (such as able to spare the time) to participate in the UK Biobank, a “healthy-volunteer” selection bias may be present—while this should not necessarily amplify differences between groups within the cohort, it may limit generalizability of our findings.<sup>17</sup> Furthermore, we did not ascertain information on various therapies for AF, such as anti-arrhythmic drugs or anticoagulants, which may have influenced the presence of AF and AF-related stroke. We sought to mitigate this by identifying incident (or first-time) diagnoses of AF (where anti-arrhythmic drugs should be less relevant), but differences in subsequent receipt of stroke reduction therapies may be an explanatory factor in differences in AF-related stroke that were observed. Information on lifestyle behaviors such as alcohol consumption was based on





ascertainment at baseline, and participants may have changed their behavior over time. However, prior research suggests most of the measured covariates are fairly stable within individuals over time.<sup>35-37</sup> While socialized medicine at least theoretically should limit disparities in health care access and delivery, it is important to emphasize that other differences in exposures (including relative wealth, environmental factors, and other culturally-related behaviors) by ethnicity that are important to health and the outcomes studied here likely remain operative. While the current models adjusted for level of education, other social determinants of health may yet have influenced the differences observed. Finally, ascertainment of several comorbidities and outcomes relied on ICD-9 and ICD-10 codes, which may not be perfectly sensitive and wherein exact timing of a particular event can be difficult to accurately infer. However, examination of these codes vs chart review has revealed excellent sensitivity and specificity for AF,<sup>38</sup> and research relying exclusively on these codes have yielded high-impact results validated by studies performed using conventional methods.<sup>4,29,39-41</sup>

**CONCLUSIONS**

Independent of established AF risk factors, White individuals experienced a heightened risk of AF compared to other ethnic groups among research participants in the United Kingdom. In contrast to observations from U.S.-based data, no significant differences in AF-associated stroke or systemic

**TABLE 2 Risk of Ischemic Stroke or Systemic Infarct According to Ethnicity in Those With Atrial Fibrillation**

	Unadjusted		Adjusted	
	HR (95% CI)	P Value	HR (95% CI)	P Value
Black	1.26 (0.68-2.36)	0.46	1.51 (0.80-2.82)	0.19
South Asian	1.09 (0.68-1.73)	0.73	0.81 (0.47-1.41)	0.46
Chinese	1.28 (0.18-9.06)	0.81	N/A <sup>a</sup>	N/A <sup>a</sup>
Multiracial	2.21 (1.10-4.42)	0.03	2.04 (0.97-4.28)	0.06

White ethnicity was used as the reference. Number of events in White individuals = 1,513 of 9,973 with AF (15%), and in the rest of the cohort = 37 of 199 (19%). Analyses were adjusted for age, sex, education, body mass index, diabetes, hypertension, coronary disease, congestive heart failure, valvular disease, chronic kidney disease, obstructive sleep apnea, smoking, and alcohol consumption. <sup>a</sup>Not applicable due to limited outcome data (number of events = 1).



**TABLE 3 Risk of Ischemic Stroke According to Ethnicity in Those With Atrial Fibrillation**

	Unadjusted		Adjusted	
	HR (95% CI)	P Value	HR (95% CI)	P Value
Black	1.28 (0.64-2.57)	0.49	1.49 (0.74-2.99)	0.27
South Asian	1.18 (0.71-1.97)	0.52	0.93 (0.51-1.70)	0.82
Chinese	1.74 (0.24-12.33)	0.58	N/A <sup>a</sup>	N/A <sup>a</sup>
Multiracial	2.42 (1.15-5.10)	0.02	2.25 (1.01-5.04)	0.048

Risk of ischemic stroke in each ethnicity in those with atrial fibrillation with White ethnicity as reference. Number of events in White individuals = 1,163 of 10,224 (11%) vs the rest of the cohort = 31 of 204 (15%). Adjusted models included age, sex, education, body mass index, diabetes, hypertension, coronary disease, valvular disease, congestive heart failure, chronic kidney disease, obstructive sleep apnea, smoking, and alcohol. <sup>a</sup>Not applicable due to limited outcome data.

embolism between ethnic groups were detected, although a relatively small number of events may have precluded sufficient power to detect differences. These findings from a population-based cohort outside the United States suggest that the ethnic differences in AF may be a global phenomenon not sufficiently explained by differences in health care access or environment. The absence of differences in stroke and systemic embolism among these AF patients in the United Kingdom may suggest extant disparities in these adverse outcomes in the United States are remediable.

**ACKNOWLEDGMENTS** This research has been conducted using data from the UK Biobank, a major biomedical database. The authors thank the UK Biobank participants that contributed to this valuable research source.

#### FUNDING SUPPORT AND AUTHOR DISCLOSURES

The UK Biobank has received funding from the UK Medical Research Council, Wellcome Trust, Department of Health, British Heart Foundation, Diabetes UK, Northwest Regional Development Agency, Scottish Government, and Welsh Assembly Government. As described in the manuscript, the MRC and Wellcome Trust played a key role in the decision to establish the UK Biobank, a large, population-based, prospective, open-access resource that would allow detailed investigations of the genetic and environmental determinants of the diseases of middle and old age. The MRC, Wellcome Trust, Department of Health, and Scottish Chief Scientist Office each have a representative on the UK Biobank Board. The MRC and Wellcome Trust fund the independent Ethics and Governance Council.<sup>16</sup> Dr Biering-Sørensen is the chief investigator of the Novo Nordisk financed “NUDGE-DM-PERSISTENCE” trial; chief investigator of the Boston Scientific financed “DANLOGIC-HF” trial; chief investigator of the Sanofi Pasteur financed “NUDGE-FLU” trial; chief investigator of the Sanofi Pasteur financed “DANFLU-1” trial; chief investigator of the Sanofi Pasteur financed “DANFLU-2” trial; steering committee member of Boston Scientific sponsored “LUX-Dx TRENDS Evaluates Diagnostics Sensors in Heart Failure Patients

Receiving Boston Scientific’s Investigational ICM System” trial; steering committee member of the Amgen sponsored GALACTIC-HF trial; steering committee member of the Boehringer Ingelheim financed EASI-KIDNEY trial; advisory board member of Sanofi Pasteur, Amgen, CSL Seqirus, and GSK; has received speaker honorarium from Bayer, Novartis, Sanofi Pasteur, GE Healthcare, and GSK; has received research grants from Boston Scientific, GE Healthcare, AstraZeneca, Novo Nordisk, and Sanofi Pasteur; and has consultant appointments with Novo Nordisk, IQVIA, and Parexel. Dr Jackson has received research grants from the National Institute of Health, specifically the National Institute on Minority Health and Health Disparities, is currently supported by 1K01HL159041 from the National Heart, Lung and Blood Institute and the American Association under award number 851386; serves as a consultant to Biosense Webster Inc, Johnson & Johnson, Sanofi, Bristol Myers Squibb, and Pfizer; and receives honoraria from Zoll LifeVest, CME Outfitters, Health Monitor, PRIME Education, and WebMD/Medscape. Dr Marcus has received funding from the NIH (NHLBI, NIBIB, and NCI), TRDRP, and PCORI; and is a consultant for and has equity in InCarda. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

**ADDRESS FOR CORRESPONDENCE:** Dr Gregory M. Marcus, Division of Cardiology, University of California-San Francisco, 505 Parnassus Avenue, M1180B, San Francisco, California 94143, USA. E-mail: [greg.marcus@ucsf.edu](mailto:greg.marcus@ucsf.edu).

#### PERSPECTIVES

**COMPETENCY IN PATIENT CARE:** Our study contributes to the growing evidence that differential access to health care systems cannot entirely account for the observed differences in AF incidence by ethnicities or races. However, these data suggest that U.S.-based disparities in AF-related stroke and systemic infarcts need not apply in other national health care systems.

**TRANSLATIONAL OUTLOOK:** Understanding the etiologies of ethnic differences in AF incidence may uncover as yet unknown mechanisms of AF pertinent to prevention strategies or novel therapies. More research is warranted to examine whether ethnic differences in AF-related stroke, as seen in the United States, persist in other countries with socialized medicine. Identifying specific (and perhaps various) explanations underlying the AF-associated stroke and systemic infarct risk differences may reveal useful strategies to assure that AF patients can achieve equity in the United States in regard to potential adverse outcomes of this common disease.

## REFERENCES

1. Stewart S, Hart CL, Hole DJ, McMurray JJV. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. *Am J Med*. 2002;113:359-364. [https://doi.org/10.1016/S0002-9343\(02\)01236-6](https://doi.org/10.1016/S0002-9343(02)01236-6)
2. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death. *Circulation*. 1998;98:946-952. <https://doi.org/10.1161/01.CIR.98.10.946>
3. Oster J, Hopewell JC, Ziberna K, et al. Identification of patients with atrial fibrillation: a big data exploratory analysis of the UK Biobank. *Physiol Meas*. 2020;41:025001. <https://doi.org/10.1088/1361-6579/ab6f9a>
4. Dewland TA, Olgin JE, Vittinghoff E, Marcus GM. Incident atrial fibrillation among Asians, Hispanics, Blacks, and Whites. *Circulation*. 2013;128:2470-2477. <https://doi.org/10.1161/CIRCULATIONAHA.113.002449>
5. Marcus GM, Olgin JE, Whooley M, et al. Racial differences in atrial fibrillation prevalence and left atrial size. *Am J Med*. 2010;123:375.e1-375.e7. <https://doi.org/10.1016/j.amjmed.2009.05.019>
6. Alonso A, Agarwal SK, Soliman EZ, et al. Incidence of atrial fibrillation in whites and African-Americans: the Atherosclerosis Risk in Communities (ARIC) study. *Am Heart J*. 2009;158:111-117. <https://doi.org/10.1016/j.ahj.2009.05.010>
7. Whitman IR, Vittinghoff E, DeFilippi CR, et al. NT-proBNP as a mediator of the racial difference in incident atrial fibrillation and heart failure. *J Am Heart Assoc*. 2019;8:e010868. <https://doi.org/10.1161/JAHA.118.010868>
8. Borzecki AM, Keith Bridgers D, Liebschutz JM, et al. Racial differences in the prevalence of atrial fibrillation among males. *J Natl Med Assoc*. 2008;100:31212-31218. [https://doi.org/10.1016/S0027-9684\(15\)31212-8](https://doi.org/10.1016/S0027-9684(15)31212-8)
9. Ugowe FE, Jackson LR, Thomas KL. Racial and ethnic differences in the prevalence, management, and outcomes in patients with atrial fibrillation: a systematic review. *Heart Rhythm*. 2018;15:1337-1345. <https://doi.org/10.1016/j.hrthm.2018.05.019>
10. Marcus GM, Alonso A, Peralta CA, et al. European ancestry as a risk factor for atrial fibrillation in African Americans. *Circulation*. 2010;122:2009-2015. <https://doi.org/10.1161/CIRCULATIONAHA.110.958306>
11. Roberts JD, Hu D, Heckbert SR, et al. Genetic investigation into the differential risk of atrial fibrillation among black and white individuals. *JAMA Cardiol*. 2016;1:442. <https://doi.org/10.1001/jamacardio.2016.1185>
12. Tsao CW, Aday AW, Almarazooq ZI, et al. Heart disease and stroke statistics—2022 update: a report from the American Heart Association. *Circulation*. 2022;145:e153-e639. <https://doi.org/10.1161/CIR.0000000000001052>
13. Magnani JW, Norby FL, Agarwal SK, et al. Racial differences in atrial fibrillation-related cardiovascular disease and mortality. *JAMA Cardiol*. 2016;1:433. <https://doi.org/10.1001/jamacardio.2016.1025>
14. Sanchez JM, Marcus GM. American Indians and atrial fibrillation. *Heart Rhythm*. 2022;3:760-765. <https://doi.org/10.1016/j.hrthm.2022.08.010>
15. Cruz-Flores S, Rabinstein A, Biller J, et al. Racial-ethnic disparities in stroke care: the American experience. *Stroke*. 2011;42:2091-2116. <https://doi.org/10.1161/STR.0b013e3182213e24>
16. Sudlow C, Gallacher J, Allen N, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. *PLoS Med*. 2015;12:e1001779. <https://doi.org/10.1371/journal.pmed.1001779>
17. Fry A, Littlejohns TJ, Sudlow C, et al. Comparison of sociodemographic and health-related characteristics of UK biobank participants with those of the general population. *Am J Epidemiol*. 2017;186:1026-1034. <https://doi.org/10.1093/aje/kwx246>
18. Teagle WL, Norris ET, Rishishwar L, Nagar SD, Jordan IK, Mariño-Ramírez L. Comorbidities and ethnic health disparities in the UK biobank. *JAMIA Open*. 2022;5:ooac057. <https://doi.org/10.1093/jamiaopen/ooac057>
19. Gill PS, Calvert M, Davis R, Davies MK, Freemantle N, Lip GYH. Prevalence of heart failure and atrial fibrillation in minority ethnic subjects: the Ethnic-Echocardiographic Heart of England Screening Study (E-ECHOES). *PLoS One*. 2011;6:e26710. <https://doi.org/10.1371/journal.pone.0026710>
20. Gillott RG, Willan K, Kain K, Sivananthan UM, Tayebjee MH. South Asian ethnicity is associated with a lower prevalence of atrial fibrillation despite greater prevalence of established risk factors: a population-based study in Bradford Metropolitan District. *Europace*. 2017;19:356-363. <https://doi.org/10.1093/europace/euw010>
21. Lau C-P, Gbadebo TD, Connolly SJ, et al. Ethnic differences in atrial fibrillation identified using implanted cardiac devices. *J Cardiovasc Electro-physiol*. 2013;24:381-387. <https://doi.org/10.1111/jce.12066>
22. Gunarathne A, Patel JV, Potluri R, Gill PS, Hughes EA, Lip GYH. Secular trends in the cardiovascular risk profile and mortality of stroke admissions in an inner city, multiethnic population in the United Kingdom (1997-2005). *J Hum Hypertens*. 2008;22:18-23. <https://doi.org/10.1038/sj.jhh.1002265>
23. Tan ESJ, Goh V, Santema BT, et al. Ethnic differences in atrial fibrillation among patients with heart failure in Asia. *ESC Heart Fail*. 2020;7:1419-1429. <https://doi.org/10.1002/ehf2.12696>
24. Office for National Statistics. Population of England and Wales. Ethnicity facts and figures. December 2022-April 2023. Accessed February 22, 2024. <https://www.ethnicity-facts-figures.service.gov.uk/uk-population-by-ethnicity/national-and-regional-populations/population-of-england-and-wales/latest/>
25. Rodriguez CJ, Soliman EZ, Alonso A, et al. Atrial fibrillation incidence and risk factors in relation to race-ethnicity and the population attributable fraction of atrial fibrillation risk factors: the Multi-Ethnic Study of Atherosclerosis. *Ann Epidemiol*. 2015;25:71-76.e1. <https://doi.org/10.1016/j.annepidem.2014.11.024>
26. Kamel H, Kleindorfer DO, Bhavne PD, et al. Rates of atrial fibrillation in black versus white patients with pacemakers. *J Am Heart Assoc*. 2016;5:e002492. <https://doi.org/10.1161/JAHA.115.002492>
27. Heckbert SR, Austin TR, Jensen PN, et al. Differences by race/ethnicity in the prevalence of clinically detected and monitor-detected atrial fibrillation. *Circ Arrhythm Electrophysiol*. 2020;13:e007698. <https://doi.org/10.1161/CIRCEP.119.007698>
28. Marcus GM, Vittinghoff E, Whitman IR, et al. Acute consumption of alcohol and discrete atrial fibrillation events. *Ann Intern Med*. 2021;174:1503-1509. <https://doi.org/10.7326/M21-0228>
29. Dukes JW, Dewland TA, Vittinghoff E, et al. Access to alcohol and heart disease among patients in hospital: observational cohort study using differences in alcohol sales laws. *BMJ*. 2016;353:i2714. <https://doi.org/10.1136/bmj.i2714>
30. Kodama S, Saito K, Tanaka S, et al. Alcohol consumption and risk of atrial fibrillation. *J Am Coll Cardiol*. 2011;57:427-436. <https://doi.org/10.1016/j.jacc.2010.08.641>
31. O'Donnell MJ, Chin SL, Rangarajan S, et al. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. *Lancet*. 2016;388:761-775. [https://doi.org/10.1016/S0140-6736\(16\)30506-2](https://doi.org/10.1016/S0140-6736(16)30506-2)
32. Kabra R, Cram P, Girotra S, Vaughan Sarrazin M. Effect of race on outcomes (stroke and death) in patients >65 years with atrial fibrillation. *Am J Cardiol*. 2015;116:230-235. <https://doi.org/10.1016/j.amjcard.2015.04.012>
33. Kabra R, Girotra S, Vaughan Sarrazin M. Refining stroke prediction in atrial fibrillation patients by addition of African-American ethnicity to CHA<sub>2</sub>DS<sub>2</sub>-VASc score. *J Am Coll Cardiol*. 2016;68:461-470. <https://doi.org/10.1016/j.jacc.2016.05.044>
34. Banda Y, Kvale MN, Hoffmann TJ, et al. Characterizing race/ethnicity and genetic ancestry for 100,000 subjects in the genetic epidemiology research on adult health and aging (GERA) cohort. *Genetics*. 2015;200:1285-1295. <https://doi.org/10.1534/genetics.115.178616>
35. Knott CS, Bell S, Britton A. The stability of baseline-defined categories of alcohol consumption during the adult life-course: a 28-year prospective cohort study. *Addiction*. 2018;113:34-43. <https://doi.org/10.1111/add.13949>
36. Schliep KC, Schisterman EF, Mumford SL, et al. Validation of different instruments for caffeine measurement among premenopausal women in the BioCycle study. *Am J Epidemiol*.

2013;177:690-699. <https://doi.org/10.1093/aje/kws283>

**37.** Modi AA, Feld JJ, Park Y, et al. Increased caffeine consumption is associated with reduced hepatic fibrosis. *Hepatology*. 2010;51:201-209. <https://doi.org/10.1002/hep.23279>

**38.** Glazer NL. Newly detected atrial fibrillation and compliance with antithrombotic guidelines. *Arch Intern Med*. 2007;167:246. <https://doi.org/10.1001/archinte.167.3.246>

**39.** Gialdini G, Nearing K, Bhave PD, et al. Peri-operative atrial fibrillation and the long-term risk of ischemic stroke. *JAMA*. 2014;312:616. <https://doi.org/10.1001/jama.2014.9143>

**40.** Birkmeyer JD, Siewers AE, Finlayson EVA, et al. Hospital volume and surgical mortality in the United States. *N Engl J Med*. 2002;346:1128-1137. <https://doi.org/10.1056/NEJMsa012337>

**41.** Whitman IR, Agarwal V, Nah G, et al. Alcohol abuse and cardiac disease. *J Am Coll Cardiol*.

2017;69:13-24. <https://doi.org/10.1016/j.jacc.2016.10.048>

---

**KEY WORDS** atrial fibrillation, ethnicity, stroke, systemic infarcts, UK Biobank

---

**APPENDIX** For supplemental tables and a figure, please see the online version of this paper.